Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases secondary to advanced renal cell carcinoma: application to France, Germany, and the United Kingdom

BACKGROUND: The use of zoledronic acid (ZOL) has recently been shown to significantly reduce the risk of new skeletal-related events (SREs) in renal cell carcinoma (RCC) patients with bone metastases. The present exploratory study assessed the cost-effectiveness of ZOL in this population, adopting a...

Descripción completa

Detalles Bibliográficos
Autores principales: Botteman, M. F., Meijboom, M., Foley, I., Stephens, J. M., Chen, Y. M., Kaura, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2010
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3197935/
https://www.ncbi.nlm.nih.gov/pubmed/20809091
http://dx.doi.org/10.1007/s10198-010-0272-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3197935/
https://www.ncbi.nlm.nih.gov/pubmed/20809091
http://dx.doi.org/10.1007/s10198-010-0272-0

Ejemplares similares